Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Shares of US biotech major Gilead Sciences closed up 2.2% at $64.62 on Friday, after its Kite subsidiary announced that the US Food and Drug Administration has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. 6 March 2021
Biotechnology
Revolo Biotherapeutics, which today rebranded itself from Immune Regulation, has outlined its mission to dramatically alter the autoimmune and allergic disease treatment landscape and the culmination of significant changes made over the past year, including: 5 March 2021
Biotechnology
Interim data from the MANTA-RAy and MANTA safety studies will help calm nerves at Belgian biotech Galapagos, with data pointing in the right direction for filgotinib. 5 March 2021
Biotechnology
The US Food and Drug Administration has approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. 5 March 2021
Biotechnology
In yet another collaboration by big pharm to help ensure production of vaccines to deal with the current pandemic, Swiss pharma giant Novartis yesterday announced its signing an initial agreement to manufacture the mRNA and bulk drug product for the COVID-19 vaccine candidate CVnCoV from German biotech CureVac. 5 March 2021
Biotechnology
The USA’s largest biotech firm Amgen, which has been fairly quiet on the M&A front for a while, announced it was splashing out nearly $2 billion on an acquisition today. 4 March 2021
Biotechnology
The US Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on treatment for children aged six to 11 years with uncontrolled moderate-to-severe asthma. 4 March 2021
Biotechnology
San Diego, USA-based Janux Therapeutics announced the close of a $56 million Series A financing round supported by top-tier investors including Avalon Ventures, OrbiMed, and RA Capital Management. The funds will help Janux advance its pre-clinical pipeline of T-cell engager immunotherapies, with a target of reaching clinical trials next year. 4 March 2021
Biotechnology
GlaxoSmithKline and Vir Biotechnology have stopped enrollment in the Phase III ACTIV trial testing VIR-7831 as a treatment for COVID-19. 4 March 2021
Biotechnology
ConserV Bioscience, a UK biotech focused on developing vaccines that protect against endemic and emergent infectious diseases, has entered into a collaboration with Belgian company eTheRNA immunotherapies. 4 March 2021
Biotechnology
US pharma major Eli Lilly and partner Incyte have released top-line results from BRAVE-AA2, a Phase III study evaluating the efficacy and safety of their once-daily JAK-inhibitor baricitinib 2mg and 4mg in adults with severe alopecia areata (AA). 4 March 2021
Biotechnology
US biotech minnow Ovid Therapeutics saw its shares leap 74% in pre-market trading this morning, and still up 33% at $3.94 early afternoon, following its announcement of a lucrative deal with existing partner. 3 March 2021
Biotechnology
Indian vaccine maker Bharat Biotech today announced the first interim analysis of its BBV152 (COVAXIN), a COVID-19 vaccine candidate. 3 March 2021
Biotechnology
CNS specialist atai Life Sciences has announced the successful closing of its $157 million Series D financing. 3 March 2021
Biotechnology
People in England and Wales who are living with moderate to severe atopic dermatitis (also known as atopic eczema) now have a new treatment option routinely available on the National Health Service (NHS). 3 March 2021
Biotechnology
The Thalassaemia International Federation (TIF) has objected to the UK´s National Institute of Health and Care Excellence (NICE) issuing of a negative recommendation for the Zynteglo (betibeglogene autotemcel). 3 March 2021
Biotechnology
US drug major AbbVie has purchased an exclusive right to acquire San Francisco-based biotech firm Mitokinin following completion of investigational new drug (IND)-enabling studies on Mitokinin's lead PINK1 compound with potential in Parkinson’s disease. 3 March 2021
Biotechnology
Argobio, a newly-created start-up studio dedicated to life sciences, today announced its launch with 50 million euros ($60.3 million) of committed capital. 3 March 2021
Biotechnology
Despite claiming success in a Phase III trial of human papillomavirus (HPV) candidate VGX-3100, shares in Inovio Pharmaceuticals fell 15% on Tuesday, as investors worried over the strength of the data. 3 March 2021
Biotechnology
Swiss biotech Idorsia has submitted for European approval for daridorexant, an investigational dual orexin receptor antagonist, in the treatment of insomnia. 3 March 2021
All news
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze